Ildiko Lingvay1, Philip Raskin, Lidia S Szczepaniak. 1. Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA. ildiko.lingvay@utsouthwestern.edu
Abstract
OBJECTIVE: Hepatic steatosis occurs in up to 78% of patients with type 2 diabetes. Studies evaluating the effect of metformin on hepatic steatosis are conflicting. Insulin is believed to be detrimental due to its lipogenic effect. Since insulin-metformin combination is commonly used for the treatment of diabetes, it is important to assess the effect of this combined therapy on hepatic steatosis. We evaluated the change in hepatic steatosis following the initiation of insulin and metformin in patients with type 2 diabetes. METHODS: Newly diagnosed treatment-naïve patients with type 2 diabetes had their hepatic triglyceride (TG) content measured by magnetic resonance spectroscopy at baseline and after 3 months of treatment with BiAsp 30 insulin, in combination with metformin. Insulin was administered twice daily and titrated to achieve normal capillary blood glucose levels. Metformin was titrated during the first month from 500 mg daily to 1000 mg bid. RESULTS: The average hepatic TG content in 19 enrolled subjects was 11.83+/-7.61% (range, 0.93-23.16%) and correlated with body mass index (r=.567). Three months of treatment reduced hepatic steatosis by 45%, with 75% of the study subjects achieving a normal level. The change in hepatic TG content was partially explained by changes in HbA1c (P=.006) and cholesterol (P=.003) levels. CONCLUSIONS: The combined treatment with insulin and metformin significantly reduced hepatic steatosis in patients with newly diagnosed type 2 diabetes.
OBJECTIVE:Hepatic steatosis occurs in up to 78% of patients with type 2 diabetes. Studies evaluating the effect of metformin on hepatic steatosis are conflicting. Insulin is believed to be detrimental due to its lipogenic effect. Since insulin-metformin combination is commonly used for the treatment of diabetes, it is important to assess the effect of this combined therapy on hepatic steatosis. We evaluated the change in hepatic steatosis following the initiation of insulin and metformin in patients with type 2 diabetes. METHODS: Newly diagnosed treatment-naïve patients with type 2 diabetes had their hepatic triglyceride (TG) content measured by magnetic resonance spectroscopy at baseline and after 3 months of treatment with BiAsp 30 insulin, in combination with metformin. Insulin was administered twice daily and titrated to achieve normal capillary blood glucose levels. Metformin was titrated during the first month from 500 mg daily to 1000 mg bid. RESULTS: The average hepatic TG content in 19 enrolled subjects was 11.83+/-7.61% (range, 0.93-23.16%) and correlated with body mass index (r=.567). Three months of treatment reduced hepatic steatosis by 45%, with 75% of the study subjects achieving a normal level. The change in hepatic TG content was partially explained by changes in HbA1c (P=.006) and cholesterol (P=.003) levels. CONCLUSIONS: The combined treatment with insulin and metformin significantly reduced hepatic steatosis in patients with newly diagnosed type 2 diabetes.
Authors: Renata Belfort; Stephen A Harrison; Kenneth Brown; Celia Darland; Joan Finch; Jean Hardies; Bogdan Balas; Amalia Gastaldelli; Fermin Tio; Joseph Pulcini; Rachele Berria; Jennie Z Ma; Sunil Dwivedi; Russell Havranek; Chris Fincke; Ralph DeFronzo; George A Bannayan; Steven Schenker; Kenneth Cusi Journal: N Engl J Med Date: 2006-11-30 Impact factor: 91.245
Authors: Adam B Mayerson; Ripudaman S Hundal; Sylvie Dufour; Vincent Lebon; Douglas Befroy; Gary W Cline; Staffan Enocksson; Silvio E Inzucchi; Gerald I Shulman; Kitt F Petersen Journal: Diabetes Date: 2002-03 Impact factor: 9.461
Authors: Kittichai Promrat; Glen Lutchman; Gabriel I Uwaifo; Renee J Freedman; Alejandro Soza; Theo Heller; Edward Doo; Marc Ghany; Ahalya Premkumar; Yoon Park; T Jake Liang; Jack A Yanovski; David E Kleiner; Jay H Hoofnagle Journal: Hepatology Date: 2004-01 Impact factor: 17.425
Authors: Christian Anderwald; Elisabeth Bernroider; Martin Krssak; Harald Stingl; Attila Brehm; Martin G Bischof; Peter Nowotny; Michael Roden; Werner Waldhäusl Journal: Diabetes Date: 2002-10 Impact factor: 9.461
Authors: A Uygun; A Kadayifci; A T Isik; T Ozgurtas; S Deveci; A Tuzun; Z Yesilova; M Gulsen; K Dagalp Journal: Aliment Pharmacol Ther Date: 2004-03-01 Impact factor: 8.171
Authors: Jonathan M Hazlehurst; Conor Woods; Thomas Marjot; Jeremy F Cobbold; Jeremy W Tomlinson Journal: Metabolism Date: 2016-01-11 Impact factor: 8.694
Authors: R M Bergenstal; H Lunt; E Franek; F Travert; J Mou; Y Qu; C J Antalis; M L Hartman; M Rosilio; S J Jacober; E J Bastyr Journal: Diabetes Obes Metab Date: 2016-08-03 Impact factor: 6.577